Prev Arrow Stocks

Revvity ($RVTY) Stock Forecast: Up 6.2% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Revvity?

Revvity, Inc. (NYSE: RVTY) is preparing to announce its financial results for the second quarter of 2024. The stock experienced significant gains in today's trading session.

Why is Revvity going up?

RVTY stock is up 6.2% on Jul 11, 2024 14:18

  • Investors are displaying confidence in Revvity, Inc. prior to its earnings call, indicating high hopes for favorable financial outcomes.
  • The upcoming executive conference call demonstrates a commitment to transparency and proactive communication with shareholders, likely enhancing investor trust.
  • The upward movement in the stock price may be attributed to expectations of strong performance in the second quarter, potentially driven by effective business strategies or initiatives for revenue growth.

RVTY Price Chart

RVTY News

Revvity To Hold Earnings Call on Monday, July 29, 2024

Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, Jetzt den vollständigen Artikel lesen

https://www.wallstreet-online.de/nachricht/18254393-revvity-to-hold-earnings-call-on-monday-july-29-2024

News Article Image Revvity To Hold Earnings Call on Monday, July 29, 2024

Revvity Price History

11.06.2024 - RVTY Stock was up 6.2%

  • Investors are displaying confidence in Revvity, Inc. prior to its earnings call, indicating high hopes for favorable financial outcomes.
  • The upcoming executive conference call demonstrates a commitment to transparency and proactive communication with shareholders, likely enhancing investor trust.
  • The upward movement in the stock price may be attributed to expectations of strong performance in the second quarter, potentially driven by effective business strategies or initiatives for revenue growth.

13.01.2024 - RVTY Stock was down 5.0%

  • The recent introduction of Revvity's clinical data science platform may not have a direct connection to RVTY's decline in the market.
  • Various other factors, including weak financial performance or unfavorable market sentiment, could have played a role in the stock's downward trend.
  • It is crucial to take into account any other developments or occurrences that might have impacted RVTY's bearish movement.

14.10.2023 - RVTY Stock was up 5.0%

  • The investigation by Pomerantz LLP might have caused some uncertainty among investors, but it did not have a significant impact on the stock's bullish movement.
  • Other positive factors, such as strong financial performance or favorable market conditions, likely contributed to the bullish movement of RVTY.
  • Investors may have been optimistic about the future prospects of Revvity, Inc., leading to increased buying interest and driving the stock price higher.
  • It is important to monitor any developments related to the investigation by Pomerantz LLP to assess any potential impact on the stock in the future.

03.10.2023 - RVTY Stock was up 5.3%

  • Revvity's disappointing Q3 report and lowered forecast initially caused a plunge in the stock, but it managed to recover and have a bullish movement.
  • The company's earnings and sales missed estimates, reflecting the impact of increased market uncertainty.
  • Despite the negative news, some articles suggest that Revvity is an undervalued gem in the medical diagnostics and research industry.
  • Other life science tool providers may have been affected by Revvity's performance, leading to a broader bearish sentiment in the industry.

31.09.2023 - RVTY Stock was down 8.4%

  • Revvity's Q3 report and lowered forecast contributed to the bearish movement in its stock.
  • The company's earnings and sales missed estimates, reflecting the impact of increased market uncertainty.
  • The demand from its pharma and biotech customers fell, further adding to the negative sentiment.
  • The disappointing performance of Revvity also had a spillover effect on other life science tool providers, dragging down their stocks as well.

30.09.2023 - RVTY Stock was down 4.6%

  • Revvity reported Q3 financial results that missed both top and bottom line estimates, with a lower-than-expected Non-GAAP EPS of $1.18 and a revenue of $670.74M (-5.8% Y/Y).
  • The company's GAAP earnings per share for the quarter were $0.08, compared to $0.67 in the same period last year, and GAAP revenue decreased from $712 million to $671 million year-over-year.
  • Analysts had estimated an EPS of $1.19 and a revenue of $694.52M for the quarter, which were not met by Revvity.
  • Additionally, Revvity declared a quarterly dividend of $0.07 per share, which may have influenced investor sentiment.
  • Overall, Revvity's weaker-than-expected financial results and missed estimates likely contributed to the bearish movement of the stock today.

25.09.2023 - RVTY Stock was down 5.1%

  • The decline in earnings is likely a significant factor contributing to the bearish movement of Revvity's stock today.
  • The lack of a positive earnings beat expectation may have disappointed investors and led to selling pressure on the stock.
  • The new partnership announcement, although positive for the long-term prospects of the company, may not have been enough to offset the negative sentiment surrounding the earnings decline.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.